fb-pixelThe Latest in Financial & Business News - The Boston Globe Skip to main content

More Life Sciences Headlines

Healey’s life sciences plan: Another $1 billion investment, with some new areas of focus

Lawmakers are so far noncommittal on funding the proposal, which will be part of a broader economic development bill the Healey administration is expected to file soon.

Moderna stock rises as COVID shot gains market share on Pfizer

Shares of the Cambridge-based biotech were up in early trading Thursday after the company reported fourth-quarter revenue that beat analysts’ expectations by gaining COVID vaccine market share on its main rival.

US lawmakers, visiting Cambridge, warn of a rising Chinese threat to US biotech

A bipartisan group of lawmakers visited Mass. this week to call for strengthening US life sciences companies, protecting their technologies, and safeguarding Americans’ genetic data.

Biogen Alzheimer’s drug launch off to slow start

Only about 2,000 patients are taking the medicine nationwide, but Biogen’s chief executive, Christopher A. Viehbacher, said he had expected the slow uptake and sees considerable demand for the medication.

A Jewish American and a Palestinian American are tackling science’s toughest challenges

Omar Abudayyeh and Jonathan Gootenberg have co-published 10 scientific papers, launched several biotech companies, and jointly run a Harvard lab.

This Cambridge startup, bootstrapped by billionaires, is developing ‘neuro-tech’ wearables

The company is designing products based on “electric medicine,” an approach that redirects brain waves through non-invasive stimulation — using sound, light, touch, and electrical pulses.

A looming threat to Greater Boston’s biotech dominance, 700 miles away

Boston-based firms that build biomanufacturing space see big opportunity in Raleigh-Durham — posing a threat that a key pillar of our region’s economy could grow faster elsewhere.

Biogen plans to shut down its controversial Alzheimer’s drug Aduhelm

The controversial approval of the Alzheimer’s disease treatment in 2021 led to scrutiny and outrage.